Literature DB >> 10908909

Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user.

S J Kish1, Y Furukawa, L Ang, S P Vorce, K S Kalasinsky.   

Abstract

The authors found that striatal levels of serotonin and those of its metabolite 5-hydroxyindoleacetic acid were severely depleted by 50 to 80% in brain of a chronic user of methylenedioxymethamphetamine (MDMA) whereas concentrations of dopamine were within the normal control range. Our data suggest that MDMA exposure in the human can cause decreased tissue stores of serotonin and therefore some of the behavioral effects of this drug of abuse could be caused by massive release and depletion of brain serotonin.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10908909     DOI： 10.1212/wnl.55.2.294

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  22 in total

1.  Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.

Authors:  H R Sumnall; L Jerome; R Doblin; M C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

Review 2.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

3.  Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry.

Authors:  Kevin Sean Murnane; Shane Alan Perrine; Brendan James Finton; Matthew Peter Galloway; Leonard Lee Howell; William Edward Fantegrossi
Journal:  Psychopharmacology (Berl)       Date:  2011-10-13       Impact factor: 4.530

Review 4.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

5.  Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.

Authors:  Ralph Buchert; Rainer Thomasius; Kay Petersen; Florian Wilke; Jost Obrocki; Bruno Nebeling; Lutz Wartberg; Pavlina Zapletalova; Malte Clausen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-17       Impact factor: 9.236

Review 6.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

7.  Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users.

Authors:  Jonathan P Roiser; Lynnette J Cook; Jason D Cooper; David C Rubinsztein; Barbara J Sahakian
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

8.  Effects of the second-generation "bath salt" cathinone alpha-pyrrolidinopropiophenone (α-PPP) on behavior and monoamine neurochemistry in male mice.

Authors:  Azizi Ray; Neha Milind Chitre; Cedrick Maceo Daphney; Bruce E Blough; Clinton E Canal; Kevin Sean Murnane
Journal:  Psychopharmacology (Berl)       Date:  2018-10-01       Impact factor: 4.530

Review 9.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

10.  Relationship between ecstasy use and depression: a study controlling for poly-drug use.

Authors:  Jonathan P Roiser; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-12-03       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.